

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

THE SYNTHESIS OF 6-PROPYL-2-SELENOURACIL, THE SELENIUM ANALOGUE OF THE ANTI-THYROID DRUG PTU

Wei-Xiao Hu^{ab}; Frank S. Guziec Jr.^a

^a Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM ^b

Department of Chemical Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang, PR of China

To cite this Article Hu, Wei-Xiao and Guziec Jr., Frank S.(1994) 'THE SYNTHESIS OF 6-PROPYL-2-SELENOURACIL, THE SELENIUM ANALOGUE OF THE ANTI-THYROID DRUG PTU', *Organic Preparations and Procedures International*, 26: 6, 682 – 684

To link to this Article: DOI: 10.1080/00304949409458168

URL: <http://dx.doi.org/10.1080/00304949409458168>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Acknowledgment.- The authors thank the following Brazilian agencies for financial support: CNPq, FAPESP and also International Foundation for Science.

REFERENCES


1. M. S. Mayer and J. R. McLaughlin, "*Handbook of Insect Pheromones and Sex Attractants*", p. 604 and references cited therein, CRC Press, Boca Raton, FL, 1991.
2. G. W. Gribble and J. K. Sanstead, *Chem. Commun.*, 735 (1973).
3. C. P. Andrieux, L. Nadjo and J. M. Saveant, *J. Electroanal. Chem.*, **26**, 147 (1970).
4. Aldrich's *Handbook of Fine Chemicals* (1994).

THE SYNTHESIS OF 6-PROPYL-2-SELENOURACIL, THE SELENIUM ANALOGUE OF THE ANTI-THYROID DRUG PTU

Submitted by Wei-Xiao Hu*† and Frank S. Guziec, Jr.
(04/28/94)


*Department of Chemistry and Biochemistry
New Mexico State University
Las Cruces, NM 88003*

Despite the fact that thiocarbonyl compounds have often proved to be important therapeutic agents, the corresponding selenocarbonyl compounds are much less well known. One such important thiocarbonyl compound is 6-propyl-2-thiouracil (**1**), commonly referred to as PTU, a thiourylene drug useful as an anti-thyroid agent.¹ For a number of years the mechanism of action of these drugs was presumed to involve inhibition of a key thyroid enzyme, 5'-iodothyronine deiodinase, (ID-1) by formation of a mixed disulfide between a cysteine residue on the enzyme and the sulfur atom of the thiourylene.^{2,3} Recently, it was discovered that ID-1 is, in fact, a selenoenzyme containing a selenocysteine residue which is necessary for full biological activity.^{4,5} Because of our interest in the chemistry of both selenocarbonyl compounds^{6,7} and anti-thyroid therapeutic agents,⁸ we sought to prepare 6-propyl-2-selenouracil (**2**), the selenium analogue of PTU to determine whether this compound could be a more effective inhibitor of ID-1, in particular because of the very mild conditions necessary for forming diselenide bonds.



1, X = S
2, X = Se

Initial attempts to prepare **2** by an alkylation-selenation sequence, commonly used to prepare acyclic selenoureas^{7,8} failed to afford the desired selenium analogue. Compound **2** could, however, be prepared by the condensation of ethyl 3-ketohexanoate with selenourea, analogous to the published procedure for the preparation of PTU.⁹ As with many selenocarbonyl compounds, 6-propylselenouracil is moderately light sensitive and easily oxidized. Decomposition can be detected by generation of finely divided red selenium, affording materials with a pale pink to red coloration.



Analytically pure **2** could be obtained as colorless crystals, pure by HPLC, by simple recrystallization. It should be noted that many selenocarbonyl compounds are prone to tautomerization to the *ene-selenol* form. This is often explained as being due to the poor π overlap between carbon and selenium in a double bond. The product 6-selenouracil shows the ¹³C NMR shifts characteristic of a selenocarbonyl compound. In particular the furthest downfield signal at δ 174 is characteristic of the selenocarbonyl carbon in a carbon-selenium double bond.⁹

The successful preparation of **2** opens the possibility of the preparation of a variety of other selenium analogues. Full biological studies on the comparisons of **2** with its sulfur analogue PTU will be published separately.¹⁰

EXPERIMENTAL SECTION

Melting points obtained on a Fisher Mel-Temp apparatus and are uncorrected. Infrared spectra were recorded with a Perkin-Elmer 1600 series FTIR. 200 MHz ¹H NMR were recorded with Varian XL 200 spectrometer; 400 MHz ¹³C NMR were recorded with a Varian Unity 400 spectrometer. Microanalysis was performed by Desert Analytics, Tucson, Arizona. All reagents were commercially available and were used without further purification.

6-Propyl-2-selenouracil (2). To selenourea (0.492 g, 4 mmol) in water (1.3 mL) and protected from light was added with stirring at room temperature ethyl 3-ketohexanoate (0.948 g, 6 mmol) along with powdered potassium hydroxide (0.336 g, 6 mmol). The mixture was stirred at room temperature for 1 hr. Water (1.3 mL) was added, and a black solid was removed by filtration. The filtrate was acidified with concentrated hydrochloric acid (1.2 mL), stirred for 30 min, and filtered. A pink solid was obtained which proved to be the selenouracil (**2**) contaminated with finely divided elemental selenium (0.25 g, 28% yield). The product was pure by HPLC (μ (C -18) (CH₃CN, H₂O, AcOH - 90:20:1). An analytically pure sample could be obtained by recrystallization from glacial acetic acid, affording colorless crystals of 6-propyl-2-selenouracil (0.095 g), mp. 189-190°. IR (KBr) 3047, 2923, 1708,

1676, 1556, 1452, 1402, 1291, 1175, 916, 631, 553 cm^{-1} , ^1H NMR ($\text{DMSO}-d_6$): δ 5.85 (s, 1H), 2.38 (t, 2.38), 1.93 (s, 2H), 1.57 (m, 2H), 0.90 (t, 3H), ^{13}C NMR ($\text{DMSO}-d_6$): δ 173.6 (C-2), 160.3 (C-4), 156.3 (C-6), 1.04.4 (C-5), 32.9 (C-7), 20.5 (C-8), 13.1 (C-9).

Anal. Calc. for $\text{C}_7\text{H}_{10}\text{N}_2\text{OSe}$: C, 38.72; H, 4.64; N 12.90. Found: C, 38.58; H, 4.66; N, 12.86

Acknowledgements.- We gratefully acknowledge the financial support of Boots Pharmaceuticals, Inc. We also thank Professor Alvin Taurog of the University of Texas Southwestern Medical Center, Dallas, TX, for helpful suggestions, and Dr. Luis Collazo for his assistance in the ^{13}C NMR studies.

REFERENCES

- † Visiting Professor at New Mexico State University (1992-1994); Current Address: Department of Chemical Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P. R. of China
1. R.C. Haynes, Jr. and F. Murad, in *Goodman and Gilman's - The Pharmacological Basis of Therapeutics*, A.G. Gilman, L.S. Goodman, T.W. Rall and F. Murad, Eds., Macmillan: New York, pp. 1401-1405, 1985.
 2. T.J. Visser, J.L. Leonard, M.M. Kaplan and P.R. Larsen, *Proc. Nat. Acad. Sci, USA*, **79**, 5080 (1982); *Chem. Abst.*, 97:139086d (1982).
 3. J.L. Leonard and T.J. Visser, in *Thyroid Hormone Metabolism*; G.H. Hennemann, Ed., Marcel Dekker, New York and Basel, pp. 189-229, 1986.
 4. M.J. Berry, L. Banu and P.R. Larsen, *Nature*, **349**, 438 (1991).
 5. M.J. Berry, J. D. Kieffer, J.W. Harney and P.R. Larsen, *J. Biol. Chem.*, **266**, 14155 (1991).
 6. F. S. Guziec, Jr., in *Organoselenium Chemistry*, D. Liotta, Ed., Wiley: New York, pp. 277-324, 1987.
 7. F. S. Guziec, Jr., in *The Chemistry of Organic Se and Te Compounds*, S. Patai, Ed., Wiley-Interscience: Chichester, pp. 215-273, 1987.
 8. G. W. Anderson, I. F. Halverstadt, W. H. Miller and R. O. Roblin, *J. Am. Chem. Soc.*, **67**, 2197 (1945).
 9. E. R. Cullen, F. S. Guziec, Jr., C. J. Murphy, T. C. Wong and K. K. Andersen, *J. Chem. Soc. Perkin Trans. 2*, 473 (1982).
 10. A. Taurog, M. Dorris, W.-X. Hu and F. S. Guziec, Jr., Unpublished results.
